Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/tinybuild-inc">tinyBuild</a> is an indie and AA video game publisher/developer focused on owning intellectual property (IP) to build long-term, multi-game, and multimedia franchises.</li>
  <li>The company has experienced significant financial distress, including substantial net losses and a sharp decline in market capitalization, leading to restructuring, layoffs, and an emergency capital raise in early 2024.</li>
  <li>Future performance is heavily reliant on a pipeline of new, higher-potential titles scheduled for release, with a strategic shift towards organic growth and owned-IP after a period of costly and underperforming acquisitions.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
tinyBuild is an indie and AA video game publisher/developer focused on owning intellectual property (IP) to build long-term, multi-game, and multimedia franchises.
  The company has experienced significant financial distress, including substantial net losses and a sharp decline in market capitalization, leading to restructuring, layoffs, and an emergency capital raise in early 2024.
  Future performance is heavily reliant on a pipeline of new, higher-potential titles scheduled for release, with a strategic shift towards organic growth and owned-IP after a period of costly and underperforming acquisitions.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

<ul>
<li>Corcel 0.44p £37.47m (CRCL.L) The Angola-Brazil focused energy Company has raised £3.6m through a subscription with a number of its existing strategic investors at 0.4p.</li>
<li>The additional capital will enable the Company to accelerate key workstreams, including the procurement of critical long lead items and the early securing of a drilling rig.</li>
<li>This will reduce exposure to supply chain bottlenecks and position the Company to commence drilling within the next 12 months. </li>
</ul>


Corcel 0.44p £37.47m (CRCL.L) The Angola-Brazil focused energy Company has raised £3.6m through a subscription with a number of its existing strategic investors at 0.4p.
The additional capital will enable the Company to accelerate key workstreams, including the procurement of critical long lead items and the early securing of a drilling rig.
This will reduce exposure to supply chain bottlenecks and position the Company to commence drilling within the next 12 months. 


Tinybuild Inc - Hybridan Small Cap Feast: 19 March 2026

<ul>
<li>CT Automotive Group 25.50p £16.93m (CTA.L) The designer, developer and supplier of interior components to the global automotive industry updates on trading.</li>
<li>The Group expects to report revenues for December FY25 of at least $113m, in line with current market expectations, and the profit before tax is expected to be at least $10.0m.</li>
<li>This is the third consecutive year of improvement in underlying profit before tax. Net debt at 31 December 2025 is expected to be $7.7m. </li>
</ul>


CT Automotive Group 25.50p £16.93m (CTA.L) The designer, developer and supplier of interior components to the global automotive industry updates on trading.
The Group expects to report revenues for December FY25 of at least $113m, in line with current market expectations, and the profit before tax is expected to be at least $10.0m.
This is the third consecutive year of improvement in underlying profit before tax. Net debt at 31 December 2025 is expected to be $7.7m. 


Tinybuild Inc - Hybridan Small Cap Feast: 5 February 2026

<ul>
<li>Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.</li>
<li>The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.</li>
<li>This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.</li>
</ul>


Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.
The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.
This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.


United States

tinyBuild is an American video game publisher and developer specializing in indie and AA titles for PC and consoles. The company focuses on owning intellectual property to build multi-game and multimedia franchises across various genres, including horror, action, simulation, and survival. tinyBuild was founded in 2011 and is headquartered in Bellevue, Washington.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

tinyBuild (TBLD LN)

Primer: tinyBuild (TBLD LN) - Aug 2026

tinyBuild is an indie and AA video game publisher/developer focused on owning intellectual property (IP) to build long-term, multi-game, and...

αSK Primers

Tinybuild Inc - Hybridan Small Cap Feast: 19 March 2026

Corcel 0.44p £37.47m (CRCL.L) The Angola-Brazil focused energy Company has raised £3.6m through a subscription with a number of its existing...

Hybridan

Tinybuild Inc - Hybridan Small Cap Feast: 5 February 2026

CT Automotive Group 25.50p £16.93m (CTA.L) The designer, developer and supplier of interior components to the global automotive industry updates on...

Hybridan

Hybridan Small Cap Feast: 13 August 2026

he clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)